Highlights

  • Nanosonics is generating robust operating cash flows from probe disinfection consumables to finance the rollout of new products.
  • High-margin trophon consumables are used with every disinfection cycle, creating repeat sales from each installed device.
  • Self-funded CORIS platform Research and Development is paid for from the cash the existing Business generates.
  • Automated ultrasound probe disinfection is the clinical need that underpins the company's established trophon product line.

Every ultrasound probe must be cleaned between patients, and every cleaning uses a consumable. Nanosonics (ASX:NAN) turns that routine into robust operating cash flow, which it is using to finance new product rollouts.

The Razor and Blade Model

Trophon systems automate ultrasound probe disinfection. Each cycle uses consumables, so installed devices generate repeat sales at high margins.

About the Company

Nanosonics focuses on infection prevention. Trophon is its established product, and CORIS is a newer platform.

Self-Funded Growth

Management is generating operating cash flows from consumables to finance new rollouts. Funding research from internal cash avoids dependence on outside capital.

The CORIS Platform

CORIS is the company's platform in development. It is funded by the existing business rather than by external fundraising.

Why Disinfection Matters

Infection control standards require reliable cleaning of reusable medical instruments, which creates steady demand.

Sector Context

Hospitals invest in infection prevention, and automation helps reduce variation in cleaning practice.

What to Watch

Consumable sales, installed base growth and CORIS progress will indicate how well the cash engine is running.

Risks to Watch

Changes in guidelines, competition and new-product timelines can affect results. Formal filings will show how rollouts progress.